TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06191133

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Conization
Description: Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
Study: NCT05903911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trans Care Web App
Description: an educational and interactive website designed to improve coping strategies of TNB individuals
Study: NCT06223724

Intervention type: DEVICE
Intervention: MAESTRO
Description: Software to measure impedance telemetry data
Study: NCT05691153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A with Dose Level 1
Description: ThisCART19A，2×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A with Dose Level 2
Description: ThisCART19A，3×10\^6 cells/kg（Single dose of Allogeneic Anti-CD19 CAR T cells will be infused）, after the lymphodepletion conditioning of fludarabine, CTX and VP-16
Study: NCT06267625

Intervention type: OTHER
Intervention: Physical Evaluations of individuals
Description: Participants will be evaluated on posture, cough strength, functional mobility and hand grip strength.They will be asked to answer the Standardized Mini Mental Test, Modified Medical Research Council Scale, Physical Activity Scale for the Elderly, Berg Balance Scale. The data to be obtained from all these evaluations are planned to be collected face to face from the participants at once and within a maximum of 1 hour.
Study: NCT06468514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural tensioning technique on radial nerve
Description: the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sliding technique on radial nerve
Description: The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
Study: NCT04934007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: 1 Hz rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS Treatment
Description: 1 Hz rTMS
Study: NCT06700109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Ice
Description: This therapy will be injected around the superolateral, superomedial, and inferomedial genicular nerves.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetate
Description: A single dose of Triamcinolone 40mg injected directly into the joint space.
Study: NCT06728293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liver Link
Description: Support Program
Study: NCT06742099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal chest tube
Description: the use of chest tubes to drain malignant pleural effusion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal chest tube
Description: the use of chest tubes to drain malignant pleural effusion

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pleurodesis
Description: the injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis
Study: NCT05659576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: 1. Sucralfate, 1 gram/10 mL oral suspension By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.May increase frequency up to 4 times per day, per physician discretion. Or~2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime.~The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard supportive care by using opioids.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One consent
Description: Patient will sign one consent form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two consent
Description: Patient will sign two consent forms.
Study: NCT05912335

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Study: NCT05431491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: Ultrafiltration through much smaller intravenous cannula than what has previously been used.
Study: NCT05865535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Study: NCT05358639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
Study: NCT05646641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength exercise
Description: The protocol consists of 8 weeks of training, consisting of 16 sessions of 50 minutes, twice a week on alternate days.
Study: NCT06390371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spotlight AQ Survey platform
Description: A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
Study: NCT05656573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-PSMA cells
Description: This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area).
Study: NCT05256381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp Alfa
Description: Subcutaneous (SC) injection.
Study: NCT04938466

Intervention type: DRUG
Intervention: Long-Acting Growth Hormone (LAGH)
Description: Long-acting growth hormone (LAGH) treatment
Study: NCT05256381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion via peripheral or central venous line.
Study: NCT05249348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Study: NCT05478707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: GLP1-RA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: supervised high intensity interval training
Study: NCT05325944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided digital intervention for NSSI
Description: Psychoeducational content, skill-based practice, and daily ecological momentary assessments will be delivered over an 8-week period.~Psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention for NSSI with coaching
Description: Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies. Daily EMAs assess NSSI and use of cognitive, behavioral, and emotion regulatory strategies. Human coaching will be used to support intervention use and engagement twice per week via text, call or email.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Psychoeducational content and psychological strategies center on cognitive behavioral principles and acceptance-based emotional regulation strategies.
Study: NCT04755062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Micronutrient-dense plant-rich Intervention
Description: The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient-dense plant-rich Intervention
Description: The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes.
Study: NCT06284252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Gaming Simulation
Description: Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
Study: NCT05694546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Post-Discharge Intervention
Description: Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
Study: NCT06449534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.
Study: NCT05789004

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Bleaching with Whiteness HP Automixx 35%
Description: * Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 35% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth Bleaching with Whiteness HP Automixx 6%
Description: * Clinical examination and taking the initial shade of the tooth with Vita Easyshade®;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* Prophylaxis with a Robson brush and prophylactic paste;~* Application of lip balm on the patient's lips;~* Placement of the labial retractor;~* Application of the gingival barrier;~* Application of Whiteness HP Automixx 6% whitening gel;~* In the session, a single application of the gel will be carried out and where it will remain on the surface of the tooth for 15 min;~* The gel must be removed from the teeth with a sucker and the teeth cleaned with gauze;~* Sensitivity/pain recording using the Pain Level Scale (Wong-Baker Faces®);~* The second bleaching session will be carried out 7 days after the first one and, if necessary, a third session can be carried out 7 days after the second one.
Study: NCT06449534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Participants in both groups were included in a structured exercise program consisting of exercises recommended in the literature. This exercise program includes joint range of motion exercises, stretching exercises and strengthening exercises and was carried out under the supervision of a physiotherapist for 6 weeks. Joint range of motion and strengthening exercises are recommended as 3 sets of 10 repetitions, and stretching exercises are recommended as 5 repetitions for 20 seconds. Exercises appropriate to the patients' clinical conditions and progression were selected by the physiotherapist and included in the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Following each exercise treatment, cold-pack will be applied for 15 minutes. During col-pack application, patients in the Group 1 group will listen to classical music selected by us, while patients in the Group 2 will rest quietly. There are a total of 40 songs by Bach, Mozart, Beethoven and Andre Rieu on our CD player, and patients have the right to choose and listen to the song they want.
Study: NCT04963270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: Satralizumab will be administered as a subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Satralizumab placebo will be administered as a subcutaneous injection
Study: NCT04934098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Wrap
Description: The material will be delivered, adapted, and oriented for the daily use of the adjustable compression wrap (Ready Wrap®). The wrap allows for easy use because it is the pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compression properties, it can be used as a therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)). The institutional protocol for the control of the lymphedema phase will be respected, in which the orthosis is used at home for the longest period possible, with the only removal for bathing and sleeping; in addition, skincare and therapeutic exercises for the upper limbs should be performed daily.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Bandage
Description: Evaluation, skincare, compression bandaging, and guidance on therapeutic exercises for upper limbs. The material used for binding is tubular mesh, foam, elastic compression bandage. Therapy will be followed according to the institutional protocol for the lymphedema reduction phase, in which it will be reassessed twice a week for 30 days.
Study: NCT06425536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home use
Description: Home use twice a day
Study: NCT05160610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multilevel intervention
Description: Multilevel intervention based on AACTT theory
Study: NCT05695664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Intravenous injection of ibuprofen 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injection
Description: Intravenous injection of Ketorolac 30 mg
Study: NCT05909527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T
Description: A single infusion of autologous CD7 CAR-T cells administered intravenously